Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
cetuximab + pembrolizumab
- Development stage
- Unknown
- Lead developer
- Merck
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
Cetuximab + pembrolizumab is a combination of two monoclonal antibodies used in oncology. Cetuximab is an epidermal growth factor receptor (EGFR) inhibitor that blocks EGFR signaling and mediates antibody-dependent cellular cytotoxicity (ADCC), leading to inhibition of tumor cell proliferation and immune-mediated tumor cell death. Pembrolizumab is a programmed cell death protein 1 (PD-1) inhibitor that blocks the interaction between PD-1 on T cells and its ligands PD-L1/PD-L2, thereby enhancing T-cell mediated anti-tumor immunity. This combination has been investigated primarily for recurrent or metastatic head and neck squamous cell carcinoma (HNSCC), particularly in patients who are platinum-resistant or platinum-ineligible[1][2][4]. The rationale for combining these agents lies in their complementary mechanisms—direct tumor targeting by cetuximab with immune checkpoint blockade by pembrolizumab—to potentially enhance anti-tumor efficacy.
- Brand names
- KeytrudaErbitux
- Other names
- pembrolizumab and cetuximab
02
Targets
PDCD1 (Programmed cell death protein 1 receptor)EGFR (Epidermal growth factor receptor)
Beyond the preview
Go deeper on cetuximab + pembrolizumab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on cetuximab + pembrolizumab.